

MD Medical Group Operating results

2Q and 1H 2024



Disclaimer

IMPORTANT NOTICE

The information, statements and opinions contained in this presentation do not constitute a public offer under any applicable legislation or an offer to sell or solicitation of any offer to buy any securities or financial instruments or any advice or recommendation with respect to such securities or other financial instruments.

FORWARD-LOOKING STATEMENTS

This presentation contains forward looking statements, which are based on the Company's current expectations and assumptions and may involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. The forward looking statements contained in this presentation are based on past trends or activities and should not be taken as a representation that such trends or activities will continue in the future. It is believed that the expectations reflected in these statements are reasonable, but they may be affected by a number of variables which could cause actual results or trends to differ materially, including, but not limited to: conditions in the market, market position of the Company, earnings, financial position, cash flows, return on capital and operating margins, anticipated investments and economic conditions; the Company's ability to obtain capital/additional finance; a reduction in demand by customers; an increase in competition; an unexpected decline in revenue or profitability; legislative, fiscal and regulatory developments, including, but not limited to, changes in environmental and health and safety regulations; exchange rate fluctuations; retention of senior management; the maintenance of labour relations; fluctuations in the cost of input costs; and operating and financial restrictions as a result of financing arrangements.


No statement in this presentation is intended to constitute a profit forecast, nor should any statements be interpreted to mean that earnings or earnings per share will necessarily be greater or lesser than those for the relevant preceding financial periods for the Company. Each forward looking statement relates only as of the date of the particular statement. Except as required by the Listing Rules, the Disclosure and Transparency Rules, the Prospectus Rules, the London Stock Exchange or otherwise by law, the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in the Company's expectations with regard there to or any change in events, conditions or circumstances on which any such statement is based.

MD Medical Group – Unique Company on the Russian Healthcare Market




- One of the largest private healthcare providers in Russia
- Leading company in multidisciplinary healthcare
- ✓ Unique competences in women's and children's healthcare
- ✓ The first public company in the industry, with the London Stock Exchange IPO back in 2012
- ✓ First level listing of ordinary shares on the Moscow Exchange (ticker: MDMG)

Investment case




MD Medical Group – #1 federal network of affordable medicine in Russia



Business Growth Dynamics






Key drivers of revenue growth in 2Q2024:

- √ in-patient and deliveries services rendered by the hospitals in Moscow and Moscow region.
- ✓ out-patient and deliveries services rendered by the regional hospitals
- ✓ out-patient services rendered by Moscow and regional clinics


Ключевые операционные результаты








IVF punctures -



In-patient days -



Out-patient visits -



Hospitals in Moscow





Lapino-1

Flagship hospital with a wide range of services

42,000 м²

MD Group

18,500 м²

Lapino-2

State-of-the-art

oncology centre

120 beds

E

27,600 m² size

Multifunctional hospital for the whole family

MD Group Michurinsky

Multifunctional Hospital for the whole family

8,755 m²

Lapino-4 Infectious diseases

4,200 m²


60 beds

261

beds

1H2024

Share of total **Group revenue**



Revenue Structure


Out-patient visits

In-patient days IVF


Deliveries



Revenue dynamic, RUB mn



2Q2024 average ticket, RUB ths



Hospitals in Moscow. Key operational results




Key operating drivers of revenue dynamic in 2Q2024

- ✓ Increase in in-patient days:
 - ✓ Oncology, gynaecology, neurology, pediatrics, traumatology
 - √ Neurosurgery in Lapino hospital
- Traditional growth in number of deliveries and IVF punctures
- ✓ Increase in out-patient visits
 - ✓ Gynaecology, pediatrics

2Q2024 average ticket dynamic

- ✓ In-patient treatments: +17.1%:
 - ✓ Higher number of intensive care days
 - ✓ Higher share of additional services (laboratory and diagnostics testing)
 - ✓ Expansion of commercial services in the oncology segment
 - √ Nearly 2x growth of plastic surgeries
- ✓ Deliveries: +23.5%
 - ✓ Growing popularity of the Lapino home obstetrics centre
 - ✓ Demand for mid and high price contracts
- ✓ Out-patient visits: +8.6%
- ✓ IVF: +4.9%


Operating indicators



8

Out-patient clinics in Moscow and Moscow region





High-end medical services for checks and treatments on the base of multidisciplinary clinics and women's and children's health clinics



580 м²


Clinic average size




11 clinics

in Moscow and Moscow region







Clinics in Moscow and Moscow region. Key operational results



Key operating drivers of revenue dynamic in 2Q2024

- ✓ Growing number of out-patient treatments due to, among other things, the opening of new clinics in Mytishchi and ZILART residential complex in 2023 and 2024
- ✓ Decline in total punctures driven by a delay in the allocation of MHI quotas

2Q2024 average ticket dynamic

- ✓ Out-patient visits: +3.1%
- ✓ IVF: +6.0%
 - ✓ Growing number of commercial punctures

Operating indicators



Hospitals in regions





Wide range of first class medical services in regions



hospitals in: Ufa, Samara, Novosibirsk, St Petersburg and Tyumen




33,000 m² 10,260 m² MD Ufa MD Novosib

15,000 м² 15,000 м² MD Samara MD Tyumen-1


MD Novosibirsk MD Lakhta **15,000 m² 4,750 m²**

4,750 m²MD Tyumen-2

 $9,000 \text{ m}^2$



#18.4% 4 188 1,869 2,163 1H2023 1H2024 2Q2023 2Q2024



Hospitals in regions. Key operational results




Key operating drivers of revenue dynamic in 2Q2024

- ✓ Increase in in-patient days:
 - ✓ Oncology, paediatrics, general surgery and therapy in Tyumen hospital and urology and traumatology in Novosibirsk hospital
 - ✓ Acquisition of new urology equipment to reduce surgery duration and increase the throughput of operating theatres
- ✓ Increase in out-patient visits:
 - ✓ Diagnostics, gynaecology, and pediatrics services provided in the hospitals of Samara, Novosibirsk and Tyumen
- ✓ Growth in number of deliveries mainly in Ufa hospital
- ✓ Decrease in MHI IVF punctures

2Q2024 average ticket dynamic

- ✓ In-patient days:+5.7%
 - ✓ New innovative diagnostic and treatment techniques
 - ✓ Sophisticated joint replacement surgeries
- ✓ Out-patient visits: +8.6%
 - ✓ Significant volume of diagnostics services rendered to oncology patients
- Deliveries: +12.6%:
 - ✓ Demand for mid and high price contracts
- ✓ IVF: +13.1%:
 - ✓ Larger share of commercial punctures



Out-patient clinics in regions





High-end medical services for checks and treatments in a "Close to home" format



 750 м^2


Clinic average size





34 clinics



27 Cities and towns







Clinics in regions. Key operational results




Key operating drivers of revenue dynamic in 2Q2024

- ✓ Increase in out-patient visits:
 - ✓ Diagnostics, rehabilitation, obstetrics and gynaecology
- ✓ Decline in IVF punctures on the back of more frozen embryo transfers


2Q2024 average ticket dynamic


- ✓ Out-patient visits: +4.9%:
 - ✓ More prenatal care contracts
- ✓ IVF: +15.6%
 - ✓ Bigger share of commercial punctures



Financial position and CAPEX







Contacts



Investor Relations Department



ir@mcclinics.ru



mcclinics.com/ru

